Medpace Australia Pty Ltd
Chimeric orthopoxvirus CF33
This licence authorises Medpace Australia Pty Ltd to conduct a clinical trial of a genetically modified (GM) chimeric orthopoxvirus as a cancer treatment in Australia.
The genetically modified organism (GMO) is genetically similar to the vaccinia virus used as a vaccine during the global smallpox eradication campaign. It has been modified by deletion of a gene so that it preferentially multiplies in and kills cancer cells. Additionally, a gene derived from humans has been introduced to facilitate the visualisation of the GMO after administration to patients by medical imaging.
The GMO will be manufactured overseas and imported into Australia. Up to 18 trial participants will receive multiple doses of the GMO over a period of 2 years.
The Risk Assessment and Risk Management Plan (RARMP) concluded that the clinical trial poses negligible risks to people or the environment. However, as this is a clinical trial under limited and controlled conditions, licence conditions have been imposed to:
- limit the duration and location of the trial
- limit the size of the trial
- restrict the spread and persistence of the GMO.
The risk analysis for this application was carried out in accordance with the Regulator’s Risk Analysis Framework.
Outlines the Regulator’s decision to issue a licence following the assessment of this application.
FAQs on the licence application and the Regulator’s decision to issue a licence for this application.
A summary of the Risk Assessment and Risk Management Plan prepared as part of the assessment of this application. It provides a brief description of the licence application, the risk assessment and risk management plan.
The final risk assessment and management plan prepared to support the Regulator's decision. It describes the GMO(s) and proposed work with the GMO(s) and provides an assessment of potential risks posed by the GMO(s). It also includes a summary of submissions received during the public consultation process.